Compare · EXOZ vs RVMD
EXOZ vs RVMD
Side-by-side comparison of eXoZymes Inc. (EXOZ) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EXOZ and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $45.31B, about 648.3x EXOZ ($69.9M).
- RVMD has been more active in the news (11 items in the past 4 weeks vs 7 for EXOZ).
- RVMD has more recent analyst coverage (25 ratings vs 0 for EXOZ).
- Company
- eXoZymes Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- $69.9M
- $45.31B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 7
- 11
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest EXOZ
- Chief Commercial Officer Perriman Damien Alan converted options into 19,612 shares, increasing direct ownership by 221% to 28,499 units (SEC Form 4)
- Chief Scientific Officer Korman Tyler Paz converted options into 32,964 shares, increasing direct ownership by 5% to 762,837 units (SEC Form 4)
- eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
- eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
- MDB Capital Holdings Provides Second Quarter 2026 Update
- SEC Form 10-Q filed by eXoZymes Inc.
- eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
- eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
- SEC Form 8-K filed by eXoZymes Inc.
- SEC Form 424B5 filed by eXoZymes Inc.
Latest RVMD
- General Counsel Cislini Jeff exercised 56,280 shares at a strike of $20.00 and sold $11,904,247 worth of shares (56,894 units at $209.24) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 55,907 units (SEC Form 4)
- Officer Goldsmith Mark A exercised 80,000 shares at a strike of $4.73 and sold $17,991,107 worth of shares (86,000 units at $209.20) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form SCHEDULE 13G filed by Revolution Medicines Inc.
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits